For adults living with persistent or treatment-resistant anxiety, researchers are studying whether ketamine may reduce anxiety symptoms through a different neurobiological pathway than conventional medications. At Ketamine Wellness Florida, treatment begins with an individualized medical evaluation—not a promise that ketamine is right for everyone.
Anxiety disorders can affect concentration, sleep, work, relationships, physical comfort, decision-making, and day-to-day quality of life. Evidence-based treatment commonly includes psychotherapy, medications, lifestyle interventions, or a combination of approaches.
For some adults, however, symptoms remain severe or return despite reasonable treatment efforts. This is sometimes described clinically as treatment-resistant or treatment-refractory anxiety, although definitions vary across studies and diagnoses.
Ketamine is being investigated because its primary pharmacology differs from traditional serotonergic anxiety medications. The current literature includes small controlled trials, open-label studies, and broader analyses of anxiety symptoms across psychiatric populations.
Small studies have explored ketamine in adults with treatment-refractory generalized anxiety, including repeated dosing approaches. These findings are clinically interesting but do not yet establish a standardized treatment protocol for GAD.
A randomized placebo-controlled crossover trial in adults with social anxiety disorder found greater improvement on a clinician-rated social anxiety scale after IV ketamine than placebo. The study was small, making replication and longer-term data important.
Many ketamine studies involve people with major depression who also have significant anxiety symptoms. Improvement in anxiety may occur alongside improvement in depressive symptoms, although the two are not necessarily identical treatment targets.
Meta-analytic evidence suggests anxiety scores can decrease within hours after ketamine in some clinical settings, with average effects also observed days later. Individual duration varies considerably.
Reviews emphasize small samples, mixed diagnoses, protocol differences, and limited long-term evidence. These limitations matter when translating research findings into individual treatment decisions.
Responsible care starts with a realistic understanding of the evidence and the limits of prediction.
Ketamine primarily affects glutamatergic signaling through NMDA receptor antagonism and downstream pathways. This differs from medications that primarily target serotonin, norepinephrine, or GABA systems.
Some studies report improvement over hours or days. That does not mean every patient responds, that relief will be complete, or that benefits will persist without reassessment.
CBT, exposure-based approaches, trauma-focused care, medication management, and other evidence-based treatments remain important. Ketamine may be considered within a broader treatment strategy rather than as an automatic substitute.
Generalized anxiety, social anxiety, panic symptoms, trauma-related hyperarousal, obsessive symptoms, and anxiety secondary to another medical or psychiatric condition can require different diagnostic and treatment approaches.
Cardiovascular status, medications, substance use, pregnancy, psychosis or mania history, and other clinical factors can change the risk-benefit calculation.
The biology of anxiety is complex. No single mechanism fully explains a patient's symptoms or ketamine's potential clinical effects.
Ketamine is a noncompetitive NMDA receptor antagonist. Glutamate is the brain's major excitatory neurotransmitter and participates in neural circuits involved in learning, memory, stress responses, and emotional processing.
Ketamine's downstream signaling has been associated with pathways involved in synaptic plasticity. Researchers are investigating whether changes in neural flexibility may contribute to improvements in mood or anxiety symptoms.
Anxiety can involve persistent threat expectations and learned associations. Experimental work is investigating whether glutamatergic modulation may influence fear learning, extinction, and related cognitive-emotional processes.
Many people with treatment-resistant depression also experience substantial anxiety. Clinical research increasingly examines whether ketamine's effects on anxiety are partly independent from, or correlated with, changes in depressive symptoms.
Candidacy is determined medically. The question is not simply whether someone “has anxiety,” but whether their diagnosis, treatment history, health, medications, and goals make IV ketamine a reasonable option to discuss.
Understanding the pattern, duration, severity, triggers, physical symptoms, functional impact, and diagnostic history helps frame the clinical problem.
Medication trials, psychotherapy, response, side effects, duration, and reasons for stopping treatment should be reviewed rather than reduced to a simple “failed treatment” label.
Blood pressure, cardiovascular history, neurological conditions, pregnancy, and other medical considerations can influence treatment safety.
Depression, PTSD, OCD, bipolar disorder, psychosis, suicidality, and other psychiatric symptoms can change both diagnosis and treatment planning.
Prescription medications, supplements, alcohol, cannabis, sedatives, stimulants, and other substances should be discussed candidly for safety.
The goal is to determine whether ketamine has a sensible role within an overall care plan—not to guarantee complete or permanent elimination of anxiety.
A careful process helps determine whether IV ketamine is medically appropriate and whether continued treatment makes sense based on response and tolerability.
Speak with our care team about your anxiety symptoms, previous treatment, medical history, and what you are hoping to improve.
A physician reviews relevant medical and psychiatric history, medications, potential contraindications, and treatment goals.
If appropriate, ketamine is administered intravenously in a controlled clinical setting with physiologic monitoring and medical oversight.
Symptoms, tolerability, function, and treatment goals are reassessed. Continued treatment should be based on the individual clinical response.
Anxiety is influenced by biology, learned behavior, relationships, trauma, sleep, physical health, stress, and environment. Even when a medication reduces symptoms, long-term functioning may still depend on skills, habits, support, and treatment of co-occurring conditions.
When appropriate, ketamine can be considered alongside established treatments rather than in isolation.
Dr. Jarrod Wilson is a South Florida physician specializing in anesthesiology. He attended medical school at the University of Miami and completed anesthesiology residency training at Mount Sinai Medical Center of Miami Beach.
His anesthesiology background includes experience with intravenous medications, patient monitoring, physiology, and medication safety. Ketamine can produce temporary changes in blood pressure, heart rate, perception, coordination, and level of awareness, making appropriate screening and monitoring important.
Ketamine Wellness Florida provides physician-guided IV ketamine care in Fort Lauderdale within The Remedy Health & Wellness. We serve adults from Fort Lauderdale, Broward County, and surrounding South Florida communities who are exploring options for persistent anxiety symptoms.
If you are researching ketamine for generalized anxiety, social anxiety, treatment-resistant anxiety, or anxiety occurring with depression, the first step is a clinical conversation. We can review the role of ketamine, discuss limitations and safety, and determine whether a physician evaluation is appropriate.
Ketamine research for anxiety continues to develop. These publications provide context for the educational information on this page.
These answers are educational and cannot determine whether ketamine is appropriate for an individual patient.
Speak with the Ketamine Wellness Florida care team in Fort Lauderdale to discuss your treatment history, ask questions about IV ketamine, and determine whether a medical evaluation may be appropriate.
For adults living with persistent or treatment-resistant anxiety, researchers are studying whether ketamine may reduce anxiety symptoms through a different neurobiological pathway than conventional medications. At Ketamine Wellness Florida, treatment begins with an individualized medical evaluation—not a promise that ketamine is right for everyone.
Anxiety disorders can affect concentration, sleep, work, relationships, physical comfort, decision-making, and day-to-day quality of life. Evidence-based treatment commonly includes psychotherapy, medications, lifestyle interventions, or a combination of approaches.
For some adults, however, symptoms remain severe or return despite reasonable treatment efforts. This is sometimes described clinically as treatment-resistant or treatment-refractory anxiety, although definitions vary across studies and diagnoses.
Ketamine is being investigated because its primary pharmacology differs from traditional serotonergic anxiety medications. The current literature includes small controlled trials, open-label studies, and broader analyses of anxiety symptoms across psychiatric populations.
Small studies have explored ketamine in adults with treatment-refractory generalized anxiety, including repeated dosing approaches. These findings are clinically interesting but do not yet establish a standardized treatment protocol for GAD.
A randomized placebo-controlled crossover trial in adults with social anxiety disorder found greater improvement on a clinician-rated social anxiety scale after IV ketamine than placebo. The study was small, making replication and longer-term data important.
Many ketamine studies involve people with major depression who also have significant anxiety symptoms. Improvement in anxiety may occur alongside improvement in depressive symptoms, although the two are not necessarily identical treatment targets.
Meta-analytic evidence suggests anxiety scores can decrease within hours after ketamine in some clinical settings, with average effects also observed days later. Individual duration varies considerably.
Reviews emphasize small samples, mixed diagnoses, protocol differences, and limited long-term evidence. These limitations matter when translating research findings into individual treatment decisions.
Responsible care starts with a realistic understanding of the evidence and the limits of prediction.
Ketamine primarily affects glutamatergic signaling through NMDA receptor antagonism and downstream pathways. This differs from medications that primarily target serotonin, norepinephrine, or GABA systems.
Some studies report improvement over hours or days. That does not mean every patient responds, that relief will be complete, or that benefits will persist without reassessment.
CBT, exposure-based approaches, trauma-focused care, medication management, and other evidence-based treatments remain important. Ketamine may be considered within a broader treatment strategy rather than as an automatic substitute.
Generalized anxiety, social anxiety, panic symptoms, trauma-related hyperarousal, obsessive symptoms, and anxiety secondary to another medical or psychiatric condition can require different diagnostic and treatment approaches.
Cardiovascular status, medications, substance use, pregnancy, psychosis or mania history, and other clinical factors can change the risk-benefit calculation.
The biology of anxiety is complex. No single mechanism fully explains a patient's symptoms or ketamine's potential clinical effects.
Ketamine is a noncompetitive NMDA receptor antagonist. Glutamate is the brain's major excitatory neurotransmitter and participates in neural circuits involved in learning, memory, stress responses, and emotional processing.
Ketamine's downstream signaling has been associated with pathways involved in synaptic plasticity. Researchers are investigating whether changes in neural flexibility may contribute to improvements in mood or anxiety symptoms.
Anxiety can involve persistent threat expectations and learned associations. Experimental work is investigating whether glutamatergic modulation may influence fear learning, extinction, and related cognitive-emotional processes.
Many people with treatment-resistant depression also experience substantial anxiety. Clinical research increasingly examines whether ketamine's effects on anxiety are partly independent from, or correlated with, changes in depressive symptoms.
Candidacy is determined medically. The question is not simply whether someone “has anxiety,” but whether their diagnosis, treatment history, health, medications, and goals make IV ketamine a reasonable option to discuss.
Understanding the pattern, duration, severity, triggers, physical symptoms, functional impact, and diagnostic history helps frame the clinical problem.
Medication trials, psychotherapy, response, side effects, duration, and reasons for stopping treatment should be reviewed rather than reduced to a simple “failed treatment” label.
Blood pressure, cardiovascular history, neurological conditions, pregnancy, and other medical considerations can influence treatment safety.
Depression, PTSD, OCD, bipolar disorder, psychosis, suicidality, and other psychiatric symptoms can change both diagnosis and treatment planning.
Prescription medications, supplements, alcohol, cannabis, sedatives, stimulants, and other substances should be discussed candidly for safety.
The goal is to determine whether ketamine has a sensible role within an overall care plan—not to guarantee complete or permanent elimination of anxiety.
A careful process helps determine whether IV ketamine is medically appropriate and whether continued treatment makes sense based on response and tolerability.
Speak with our care team about your anxiety symptoms, previous treatment, medical history, and what you are hoping to improve.
A physician reviews relevant medical and psychiatric history, medications, potential contraindications, and treatment goals.
If appropriate, ketamine is administered intravenously in a controlled clinical setting with physiologic monitoring and medical oversight.
Symptoms, tolerability, function, and treatment goals are reassessed. Continued treatment should be based on the individual clinical response.
Anxiety is influenced by biology, learned behavior, relationships, trauma, sleep, physical health, stress, and environment. Even when a medication reduces symptoms, long-term functioning may still depend on skills, habits, support, and treatment of co-occurring conditions.
When appropriate, ketamine can be considered alongside established treatments rather than in isolation.
Dr. Jarrod Wilson is a South Florida physician specializing in anesthesiology. He attended medical school at the University of Miami and completed anesthesiology residency training at Mount Sinai Medical Center of Miami Beach.
His anesthesiology background includes experience with intravenous medications, patient monitoring, physiology, and medication safety. Ketamine can produce temporary changes in blood pressure, heart rate, perception, coordination, and level of awareness, making appropriate screening and monitoring important.
Ketamine Wellness Florida provides physician-guided IV ketamine care in Fort Lauderdale within The Remedy Health & Wellness. We serve adults from Fort Lauderdale, Broward County, and surrounding South Florida communities who are exploring options for persistent anxiety symptoms.
If you are researching ketamine for generalized anxiety, social anxiety, treatment-resistant anxiety, or anxiety occurring with depression, the first step is a clinical conversation. We can review the role of ketamine, discuss limitations and safety, and determine whether a physician evaluation is appropriate.
Ketamine research for anxiety continues to develop. These publications provide context for the educational information on this page.
These answers are educational and cannot determine whether ketamine is appropriate for an individual patient.
Speak with the Ketamine Wellness Florida care team in Fort Lauderdale to discuss your treatment history, ask questions about IV ketamine, and determine whether a medical evaluation may be appropriate.